Drug Approval | January 17, 2022
Strides receives USFDA approval for influenza medicine
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
In-house wet testing with live Omicron virus demonstrated that the Antigen test detects the Omicron variant with comparable sensitivity to other variants
The last date to apply for this program is 18th January 2022
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Subscribe To Our Newsletter & Stay Updated
